Break it Down: Island strengthens IP and advances FDA pathway for key antiviral

Island Pharmaceuticals is strengthening its antiviral IP and progressing key FDA engagement as it advances its Galidesivir program.

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Tylah Tully looks at Island Pharmaceuticals (ASX:ILA), who is strengthening its antiviral IP and is progressing key FDA engagement as it advances its Galidesivir program.

Watch the video to hear the details.

While Island Pharmaceuticals is a Stockhead advertiser, it did not sponsor this content.

Originally published as Break it Down: Island strengthens IP and advances FDA pathway for key antiviral